Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
437 stopped studies mapped to Squamous Cell Carcinoma and descendants · 91% state a reason
Over the 437 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04862455 | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic… | Phase 2 | terminated | Apr 28, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | N/A | terminated | Jan 14, 2010 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients…(OPPIDOM) | N/A | terminated | Mar 17, 2021 | Institut de cancérologie Strasbourg Europe | organisationnal reason | Other (stated, no rule matched) |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or… | N/A | withdrawn | Sep 19, 2024 | Duke University | Changing priorities of portfolio | Sponsor / business decision |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3… | Phase 1 / Phase 2 | withdrawn | Dec 30, 2022 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell…(HN1901) | Phase 2 | terminated | Jun 24, 2020 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | unmet primary endpoint | Other (stated, no rule matched) |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung… | Phase 1 | terminated | Dec 15, 2022 | Mythic Therapeutics | Business decision | Sponsor / business decision |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage… | Early Phase 1 | withdrawn | May 6, 2023 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell…(ELEVATE HNSCC) | Phase 2 | terminated | Apr 22, 2021 | Gilead Sciences | Sponsor decision to terminate study | Sponsor / business decision |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Phase 1 / Phase 2 | terminated | Apr 3, 2019 | NeoImmuneTech | Strategic decision by sponsor | Sponsor / business decision |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT06046482 | Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for… | Phase 2 | terminated | Sep 21, 2023 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT02549638 | Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell… | — | terminated | Sep 15, 2015 | Mayo Clinic | Lack of funding, slow accrual | Enrollment / accrual |
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and… | Phase 3 | terminated | Jul 7, 2020 | EMD Serono Research & Development Institute, Inc. | Study has crossed the pre-defined futility boundary at the Interim Analysis. | Efficacy / futility |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual… | Phase 3 | terminated | Jul 7, 2020 | National Cancer Institute (NCI) | External information | Other (stated, no rule matched) |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04996849 | Contemporary Characteristics of Penile Cancer | — | terminated | Aug 9, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05061420 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Sep 29, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06338657 | FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer | Phase 1 | terminated | Mar 29, 2024 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT04989387 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Aug 4, 2021 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal… | N/A | withdrawn | May 20, 2024 | Hebei Medical University Fourth Hospital | The primary reason for termination was difficulty in recruitment | Enrollment / accrual |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT06762808 | Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC | Phase 2 | withdrawn | Jan 8, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic… | Phase 2 | terminated | Oct 25, 2017 | Hebei Medical University Fourth Hospital | This study was voluntarily terminated after investigator assessment, with no safety concerns… | Safety / toxicity |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by… | Phase 2 | withdrawn | Jun 26, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | — | withdrawn | Apr 12, 2024 | Wake Forest University Health Sciences | PI not moving forward with study at our institution | Other (stated, no rule matched) |
| NCT02892201 | Pembrolizumab in HNSCC With Residual Disease After Radiation | Phase 2 | terminated | Sep 8, 2016 | Yale University | Low enrollment | Enrollment / accrual |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined… | Phase 1 / Phase 2 | terminated | Apr 28, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer… | N/A | terminated | May 16, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | Early Phase 1 | withdrawn | Oct 17, 2023 | Mitchell Machtay | The study was not initiated due to funding constraints and will not proceed in its current design. | Funding |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05879484 | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative… | Phase 1 / Phase 2 | withdrawn | May 30, 2023 | National Cancer Institute (NCI) | Study was never opened for enrollment as the CRADA was never executed | Enrollment / accrual |
| NCT03440437 | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | Phase 1 / Phase 2 | terminated | Feb 22, 2018 | invoX Pharma Limited | Business Decision | Sponsor / business decision |
| NCT03737721 | The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and…(UNSCARRed) | Phase 2 | terminated | Nov 9, 2018 | AHS Cancer Control Alberta | Loss of Pharma Support | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With… | Phase 2 | terminated | Jul 18, 2022 | BeiGene | Due to modification of company strategy. | Sponsor / business decision |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | — | withdrawn | Sep 23, 2019 | ProgenaBiome | Sponsor decision | Sponsor / business decision |
| NCT01720563 | A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell… | Phase 2 | terminated | Nov 2, 2012 | PhytoHealth Corporation | Change study drug dosage form | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jan 23, 2026source: clinicaltrials